FWCM
GSK icon

Ferguson Wellman Capital Management’s GSK GSK Stock Holding History

Ferguson Wellman Capital Management’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-8,706
Closed -$444K – 349
2020
Q2 		$444K Sell
8,706
-100,148
-92% -$5.14M 0.01% 264
2020
Q1 		$5.16M Buy
108,854
+4,740
+5% +$253K 0.19% 102
2019
Q4 		$6.12M Buy
104,114
+4,015
+4% +$223K 0.18% 115
2019
Q3 		$5.34M Buy
100,099
+3,456
+4% +$178K 0.17% 112
2019
Q2 		$4.83M Buy
96,643
+1,791
+2% +$89.9K 0.16% 112
2019
Q1 		$4.96M Buy
94,852
+3,733
+4% +$187K 0.17% 113
2018
Q4 		$4.35M Buy
91,119
+84,806
+1,343% +$4.18M 0.17% 122
2018
Q3 		$317K Hold
6,313
– – 0.01% 277
2018
Q2 		$318K Hold
6,313
– – 0.01% 284
2018
Q1 		$308K Buy
6,313
+160
+3% +$7.45K 0.01% 290
2017
Q4 		$273K Buy
6,153
+80
+1% +$3.7K 0.01% 307
2017
Q3 		$308K Sell
6,073
-400
-6% -$20.3K 0.01% 282
2017
Q2 		$349K Sell
6,473
-200
-3% -$10.7K 0.01% 269
2017
Q1 		$352K Sell
6,673
-1,485
-18% -$75.3K 0.01% 262
2016
Q4 		$393K Buy
8,158
+1,085
+15% +$53.6K 0.02% 252
2016
Q3 		$381K Sell
7,073
-560
-7% -$30.7K 0.02% 239
2016
Q2 		$414K Buy
7,633
+213
+3% +$11.2K 0.02% 237
2016
Q1 		$376K Buy
7,420
+80
+1% +$3.98K 0.02% 238
2015
Q4 		$370K Sell
7,340
-405
-5% -$20.6K 0.02% 258
2015
Q3 		$372K Buy
7,745
+432
+6% +$22.5K 0.02% 255
2015
Q2 		$381K Buy
7,313
+1,080
+17% +$60.8K 0.02% 256
2015
Q1 		$360K Sell
6,233
-36
-0.6% -$2.06K 0.01% 262
2014
Q4 		$335K Sell
6,269
-344
-5% -$19.2K 0.01% 272
2014
Q3 		$380K Hold
6,613
– – 0.02% 250
2014
Q2 		$442K Hold
6,613
– – 0.02% 244
2014
Q1 		$442K Sell
6,613
-225
-3% -$15.2K 0.02% 232
2013
Q4 		$456K Buy
6,838
+138
+2% +$8.95K 0.02% 225
2013
Q3 		$420K Buy
+6,700
New +$431K 0.02% 227

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
BCIM
Black Creek Investment Management Toronto, Ontario, Canada $1.86B AUM 15.33% 1-Year Est. Return

Ferguson Wellman Capital Management's GSK Position: Q3 2020 in Review

Ferguson Wellman Capital Management sold out of GSK (GSK) in Q3 2020, closing a stake of 8,706 shares — an estimated $444K sold.

Ferguson Wellman Capital Management first reported a position in GSK in Q3 2013 and held it in 28 quarters. The position peaked at $6.12M in Q4 2019. 826 funds tracked by Wall St. Rank hold GSK as of Q3 2020.

  • Ferguson Wellman Capital Management reported no remaining GSK position as of Q3 2020 after selling out during the quarter.
  • Ferguson Wellman Capital Management sold 8,706 GSK shares in Q3 2020, an estimated $444K.
  • Ferguson Wellman Capital Management first reported a position in GSK in Q3 2013 and held it in 28 quarters.
  • Ferguson Wellman Capital Management's GSK position peaked at $6.12M in Q4 2019.
  • 826 funds tracked by Wall St. Rank held GSK as of Q3 2020.

Based on Ferguson Wellman Capital Management's 13F filing for Q3 2020, filed 13 Oct 2020.